Free Trial

Brokerages Set LifeMD, Inc. (NASDAQ:LFMD) Target Price at $12.00

LifeMD logo with Medical background

LifeMD, Inc. (NASDAQ:LFMD - Get Free Report) has been given an average rating of "Buy" by the seven analysts that are presently covering the firm, MarketBeat reports. One analyst has rated the stock with a hold recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have updated their coverage on the stock in the last year is $12.86.

LFMD has been the topic of several research reports. HC Wainwright restated a "buy" rating and set a $14.00 price objective on shares of LifeMD in a report on Wednesday, April 30th. Lake Street Capital set a $18.00 price target on LifeMD and gave the stock a "buy" rating in a report on Thursday. Finally, BTIG Research increased their price objective on shares of LifeMD from $15.00 to $18.00 and gave the company a "buy" rating in a research note on Wednesday, June 18th.

View Our Latest Analysis on LFMD

Insider Activity at LifeMD

In related news, insider Stefan Galluppi sold 85,000 shares of the company's stock in a transaction that occurred on Friday, June 13th. The shares were sold at an average price of $12.38, for a total transaction of $1,052,300.00. Following the sale, the insider directly owned 80,449 shares in the company, valued at approximately $995,958.62. This represents a 51.38% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Marc David Benathen sold 50,000 shares of LifeMD stock in a transaction on Tuesday, June 17th. The shares were sold at an average price of $14.01, for a total value of $700,500.00. Following the completion of the transaction, the chief financial officer owned 339,554 shares of the company's stock, valued at approximately $4,757,151.54. This trade represents a 12.84% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 346,995 shares of company stock worth $4,119,172. Company insiders own 18.40% of the company's stock.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in LFMD. GAMMA Investing LLC purchased a new stake in shares of LifeMD in the first quarter worth about $35,000. CWM LLC boosted its stake in LifeMD by 17.5% during the first quarter. CWM LLC now owns 9,050 shares of the company's stock valued at $49,000 after buying an additional 1,351 shares during the period. ProShare Advisors LLC purchased a new position in LifeMD during the fourth quarter worth about $51,000. Oxford Asset Management LLP bought a new position in LifeMD in the 4th quarter worth about $52,000. Finally, Balyasny Asset Management L.P. purchased a new stake in shares of LifeMD in the 4th quarter valued at about $52,000. Institutional investors own 35.52% of the company's stock.

LifeMD Stock Up 1.5%

LFMD traded up $0.18 during trading on Thursday, reaching $11.96. 1,132,402 shares of the stock traded hands, compared to its average volume of 1,083,815. The stock's 50-day moving average is $11.62 and its 200 day moving average is $7.68. LifeMD has a 12 month low of $3.99 and a 12 month high of $15.84. The stock has a market capitalization of $543.56 million, a PE ratio of -35.18 and a beta of 2.40.

LifeMD (NASDAQ:LFMD - Get Free Report) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.05. The company had revenue of $65.70 million during the quarter, compared to the consensus estimate of $62.47 million. As a group, equities research analysts anticipate that LifeMD will post -0.56 EPS for the current year.

About LifeMD

(Get Free Report

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.

Further Reading

Analyst Recommendations for LifeMD (NASDAQ:LFMD)

Should You Invest $1,000 in LifeMD Right Now?

Before you consider LifeMD, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LifeMD wasn't on the list.

While LifeMD currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines